Please login to the form below

Not currently logged in
Email:
Password:

anxiety

This page shows the latest anxiety news and features for those working in and with pharma, biotech and healthcare.

Low-dose LSD looks safe for Alzheimer’s patients, but will it work?

Low-dose LSD looks safe for Alzheimer’s patients, but will it work?

Earlier studies point to potential benefits for LSD in depression, anxiety, and substance abuse, and Eleusis’ hope is that low dose LSD may also have significant potential in treating Alzheimer’s,

Latest news

More from news
Approximately 1 fully matching, plus 148 partially matching documents found.

Latest Intelligence

  • Growing up as a patient is hard to manage Growing up as a patient is hard to manage

    Not only do many patients experience anxiety as a result of an unfamiliar care team, undefined degree of control or unexpected changes to therapy, but they can also face system-level

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    However, the HTA acknowledges the limitations of the index, noting that “the DLQI has limited validity in some people, and may miss anxiety and depression.”.

  • Changing healthcare communications Changing healthcare communications

    Replacing anxiety with confidence, mediocrity with purpose. By David Hunt and Lou Shipley. ... But only if we replace anxiety with confidence, mediocrity with purpose, and attract the brightest, smartest and most creative minds to join our cause.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    There were also significant improvements for AbbVie’s drug over Humira on quality of life measures and over Stelara on anxiety and depression, and risankizumab did better than both comparator drugs

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Galbraith is concerned about the rise in reported anxiety and mental health problems in young people, with young women most vulnerable.

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

  • Dr Niall Murphy and Pierre Schwich join Pharnext Dr Niall Murphy and Pierre Schwich join Pharnext

    Prior to this, Dr Murphy served as a unit leader for a team of scientists collaborating on research in the areas of addition biology, Alzheimer's disease, anxiety, depression and neurotoxicity

  • Turing names Eliseo Salinas as head of R&D Turing names Eliseo Salinas as head of R&D

    Salinas has played a leading role in numerous programmes for a range of diseases and disorders, with specific focus on central nervous systems (CNS) condition such as depression and anxiety, schizophrenia,

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 30 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics